◼

News

All News

Keep up to date with the world of Septerna

All

2025

2024

2023

2022

01.06.25

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr.

12.18.24

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna , a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43 rd

11.20.24

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support

10.30.24

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO)

10.24.24

Septerna Prices Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of

09.30.24

Septerna Presents New Preclinical Data at ASBMR 2024 Highlighting Therapeutic Potential of Oral Small Molecule Parathyroid Hormone 1 Receptor (PTH1R) Agonists for Hypoparathyroidism

In addition to maintaining serum calcium control, PTH1R agonists upregulated bone turnover biomarkers and active Vitamin D levels over 28 days of dosing in a preclinical model Septerna’s lead product candidate, SEP-786, now in Phase 1 clinical development SOUTH SAN FRANCISCO, Calif.

09.27.24

Septerna Announces Initiation of Phase 1 Clinical Trial with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Trial Initiation Marks Septerna’s Transition to a Clinical-Stage Company Developing a Portfolio of Oral Small Molecule GPCR-Targeted Medicines Phase 1 Clinical Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-786 in Healthy Volunteers SOUTH SAN

09.25.24

Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles

Jae Kim, M.D., joins as Chief Medical Officer to lead strengthened and expanded clinical development team as first GPCR-targeted oral small molecule enters clinical development SOUTH SAN FRANCISCO, Calif. – September 25, 2024 – Septerna , a clinical-stage biotechnology company pioneering a new

06.03.24

Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic Potential of its GPCR Drug Discovery Platform

Oral, small molecule parathyroid hormone 1 receptor (PTH1R) agonist maintained serum calcium control over 28-day dosing in a preclinical hypoparathyroidism model PTH1R program for hypoparathyroidism expected to enter Phase 1 in late 2024 Oral, thyroid stimulating hormone receptor (TSHR) antagonist

05.28.24

Septerna to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. – May 28, 2024 – Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that management will participate in the Jefferies Global Healthcare Conference in New York

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20

News

All News

Pioneering a New Era of GPCR Drug Discovery